Litcius/Paper detail

TLR4 and SARM1 modulate survival and chemoresistance in an HPV-positive cervical cancer cell line

Mirian Galliote Morale, Rodrigo Esaki Tamura, Ricardo Cesar Cintra, Natália Meneses Araújo, Luisa L. Villa

2022Scientific Reports14 citationsDOIOpen Access PDF

Abstract

Human Papillomavirus is responsible for a wide range of mucosal lesions and tumors. The immune system participate in tumorigenesis in different ways. For example, signaling pathways triggered by Toll-like receptors (TLR) play a role in chemotherapy resistance in several tumor types and are candidates for contributing to the development of HPV-induced tumors. Here, we studied the receptor TLR4 and the adaptor molecule SARM1 in HeLa cells, an HPV-positive cervical cancer cell line. Knocking out of these genes individually proved to be important for maintaining cell viability and proliferation. TLR4 knock out cells were more sensitive to cisplatin treatment, which was illustrated by an increased frequency of apoptotic cells. Furthermore, TLR4 and SARM1 modulated ROS production, which was induced by cell death in response to cisplatin. In conclusion, TLR4 and SARM1 are important for therapy resistance and cervical cancer cell viability and may be relevant clinical targets.

Topics & Concepts

CisplatinCancer researchHeLaCarcinogenesisApoptosisBiologyViability assayCervical cancerTLR4CellCancerSignal transductionMedicineCell biologyChemotherapyGeneticsImmune Response and InflammationImmunotherapy and Immune ResponsesCancer Research and Treatments
TLR4 and SARM1 modulate survival and chemoresistance in an HPV-positive cervical cancer cell line | Litcius